FI973063L - Guaniinijohdannainen - Google Patents

Guaniinijohdannainen Download PDF

Info

Publication number
FI973063L
FI973063L FI973063A FI973063A FI973063L FI 973063 L FI973063 L FI 973063L FI 973063 A FI973063 A FI 973063A FI 973063 A FI973063 A FI 973063A FI 973063 L FI973063 L FI 973063L
Authority
FI
Finland
Prior art keywords
guanine derivative
guanine
derivative
Prior art date
Application number
FI973063A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973063A0 (fi
FI973063A7 (fi
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI973063(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI973063A0 publication Critical patent/FI973063A0/fi
Publication of FI973063A7 publication Critical patent/FI973063A7/fi
Publication of FI973063L publication Critical patent/FI973063L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI973063A 1995-01-20 1996-01-19 Guaniinijohdannainen FI973063L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (3)

Publication Number Publication Date
FI973063A0 FI973063A0 (fi) 1997-07-18
FI973063A7 FI973063A7 (fi) 1997-09-18
FI973063L true FI973063L (fi) 1997-09-18

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973063A FI973063L (fi) 1995-01-20 1996-01-19 Guaniinijohdannainen

Country Status (40)

Country Link
US (1) US6107302A (Sortimente)
EP (1) EP0804436B1 (Sortimente)
JP (1) JP3176633B2 (Sortimente)
KR (1) KR100376074B1 (Sortimente)
CN (1) CN1049893C (Sortimente)
AP (1) AP662A (Sortimente)
AR (1) AR002270A1 (Sortimente)
AT (1) ATE302777T1 (Sortimente)
AU (1) AU702794B2 (Sortimente)
BG (1) BG63393B1 (Sortimente)
BR (1) BR9606768A (Sortimente)
CA (1) CA2210799C (Sortimente)
CY (1) CY2531B1 (Sortimente)
CZ (1) CZ297065B6 (Sortimente)
DE (1) DE69635106T2 (Sortimente)
DK (1) DK0804436T3 (Sortimente)
EA (1) EA000364B1 (Sortimente)
EE (1) EE03528B1 (Sortimente)
ES (1) ES2248806T3 (Sortimente)
FI (1) FI973063L (Sortimente)
GB (1) GB9501178D0 (Sortimente)
GE (1) GEP20001940B (Sortimente)
HR (1) HRP960024B1 (Sortimente)
HU (1) HU222993B1 (Sortimente)
IL (1) IL116831A (Sortimente)
IN (1) IN182468B (Sortimente)
IS (1) IS2268B (Sortimente)
NO (1) NO315558B1 (Sortimente)
NZ (1) NZ298851A (Sortimente)
OA (1) OA10499A (Sortimente)
PL (1) PL182175B1 (Sortimente)
RO (1) RO118693B1 (Sortimente)
RS (1) RS49518B (Sortimente)
SI (1) SI0804436T1 (Sortimente)
SK (1) SK285329B6 (Sortimente)
TR (1) TR199700656T1 (Sortimente)
UA (1) UA46001C2 (Sortimente)
UY (1) UY25779A1 (Sortimente)
WO (1) WO1996022291A1 (Sortimente)
ZA (1) ZA96449B (Sortimente)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ZA97400B (en) * 1996-01-19 1997-11-13 Glaxo Group Ltd Valaciclovir.
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CA2278474A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
KR100774271B1 (ko) * 2001-09-07 2007-11-08 테바 파마슈티컬 인더스트리즈 리미티드 발라사이클로비르 염산염의 결정질 형태
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CN1307177C (zh) * 2001-11-14 2007-03-28 特瓦制药工业有限公司 伐昔洛韦的合成与纯化
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006011874A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries, Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ATE199719T1 (de) * 1993-06-10 2001-03-15 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
EA000364B1 (ru) 1999-06-24
HU222993B1 (hu) 2004-01-28
JPH11503718A (ja) 1999-03-30
HUP9801836A3 (en) 1999-06-28
EP0804436B1 (en) 2005-08-24
NZ298851A (en) 1999-01-28
UY25779A1 (es) 2000-08-21
CZ229497A3 (en) 1997-12-17
FI973063A0 (fi) 1997-07-18
AU702794B2 (en) 1999-03-04
NO973326L (no) 1997-09-16
EP0804436A1 (en) 1997-11-05
RS49518B (sr) 2006-10-27
SI0804436T1 (sl) 2006-02-28
GB9501178D0 (en) 1995-03-08
IL116831A (en) 1998-10-30
EE03528B1 (et) 2001-10-15
IL116831A0 (en) 1996-05-14
JP3176633B2 (ja) 2001-06-18
GEP20001940B (en) 2000-02-05
BG101833A (bg) 1998-04-30
DE69635106T2 (de) 2006-06-08
WO1996022291A1 (en) 1996-07-25
AP9701058A0 (en) 1997-10-31
NO973326D0 (no) 1997-07-18
IS2268B (is) 2007-07-15
KR19980701525A (ko) 1998-05-15
OA10499A (en) 2002-04-10
EA199700124A1 (ru) 1997-12-30
YU3396A (sh) 1998-12-23
TR199700656T1 (xx) 1998-03-21
NO315558B1 (no) 2003-09-22
PL182175B1 (pl) 2001-11-30
HUP9801836A2 (hu) 1999-05-28
ES2248806T3 (es) 2006-03-16
AP662A (en) 1998-08-19
ZA96449B (en) 1996-08-07
BR9606768A (pt) 1997-12-30
AU4453996A (en) 1996-08-07
DK0804436T3 (da) 2005-12-27
RO118693B1 (ro) 2003-09-30
IS4527A (is) 1997-07-15
SK96597A3 (en) 1998-02-04
PL321326A1 (en) 1997-12-08
SK285329B6 (sk) 2006-11-03
CA2210799A1 (en) 1996-07-25
HRP960024B1 (en) 2005-08-31
MX9705462A (es) 1997-10-31
ATE302777T1 (de) 2005-09-15
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
HRP960024A2 (en) 1997-10-31
AR002270A1 (es) 1998-03-11
CY2531B1 (en) 2006-04-12
US6107302A (en) 2000-08-22
DE69635106D1 (de) 2005-09-29
CN1179159A (zh) 1998-04-15
KR100376074B1 (ko) 2003-06-02
EE9700175A (et) 1998-02-16
UA46001C2 (uk) 2002-05-15
FI973063A7 (fi) 1997-09-18
CA2210799C (en) 2008-06-10
CZ297065B6 (cs) 2006-08-16
IN182468B (Sortimente) 1999-04-17

Similar Documents

Publication Publication Date Title
DK0804436T3 (da) Guaninderivat
DE69522717D1 (de) Chinazolinderivate
DE69611361D1 (de) Chinazolin-derivate
NO974103L (no) Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de) Chinazolin-derivate
PT833828E (pt) Derivados de rapamicina
BR9611834A (pt) Derivados de oximetóxi-3-aril-pirona
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
NO964667D0 (no) Purin-6-on-derivater
DE69601527D1 (de) Pyrrolylbenzimidazol-Derivate
ATA100695A (de) Prothrombin-derivate
ATE240307T1 (de) Diarylalkenylamin-derivate
DE69627830D1 (de) Pyrazol-derivate
DK0723963T3 (da) 4-Amino-benzoylguanidin-derivater
ATE177102T1 (de) Chromanderivate
DE59610106D1 (de) Fluorbenzylether-Derivate
DK0843675T3 (da) Aza-anthracyclinonderivater
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
ATE202088T1 (de) 4-mercapto-benzoylguanidin-derivate
DE69620514D1 (de) 5-aminoflavon-derivate
ATA45796A (de) Lysin-prolin-derivate
DE59600405D1 (de) Gehhilfe
DK0705833T3 (da) DC-89-derivat
FI950104A0 (fi) Isolerad yttervaegg till timmerhus
BR9603733A (pt) Derivados de cloropiridilcarbonila

Legal Events

Date Code Title Description
FD Application lapsed